CN117018143A - Traditional Chinese medicine composition for resisting non-alcoholic fatty liver disease and preparation method thereof - Google Patents
Traditional Chinese medicine composition for resisting non-alcoholic fatty liver disease and preparation method thereof Download PDFInfo
- Publication number
- CN117018143A CN117018143A CN202311159817.9A CN202311159817A CN117018143A CN 117018143 A CN117018143 A CN 117018143A CN 202311159817 A CN202311159817 A CN 202311159817A CN 117018143 A CN117018143 A CN 117018143A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- raw
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 16
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 16
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 16
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 16
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 16
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 16
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 16
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 16
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 16
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 10
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 9
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 9
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 9
- 235000011438 Albizia odoratissima Nutrition 0.000 claims abstract description 8
- 241000132012 Atractylodes Species 0.000 claims abstract description 8
- 241000209205 Coix Species 0.000 claims abstract description 8
- 244000197580 Poria cocos Species 0.000 claims abstract description 8
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 8
- 235000006533 astragalus Nutrition 0.000 claims abstract description 8
- 235000021419 vinegar Nutrition 0.000 claims abstract description 8
- 239000000052 vinegar Substances 0.000 claims abstract description 8
- 241000220317 Rosa Species 0.000 claims abstract description 7
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 7
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 4
- 244000164480 Curcuma aromatica Species 0.000 claims abstract description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 4
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 3
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 6
- 240000000559 Albizia odoratissima Species 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241001061264 Astragalus Species 0.000 claims description 5
- 240000009138 Curcuma zedoaria Species 0.000 claims description 5
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims description 5
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 210000004233 talus Anatomy 0.000 claims description 5
- 235000019509 white turmeric Nutrition 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 208000026435 phlegm Diseases 0.000 abstract description 16
- 210000000952 spleen Anatomy 0.000 abstract description 11
- 230000014759 maintenance of location Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 30
- 210000004185 liver Anatomy 0.000 description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 description 14
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 241001092040 Crataegus Species 0.000 description 12
- 208000008589 Obesity Diseases 0.000 description 12
- 235000020824 obesity Nutrition 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 102000004311 liver X receptors Human genes 0.000 description 11
- 108090000865 liver X receptors Proteins 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 101150092476 ABCA1 gene Proteins 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 241000220433 Albizia Species 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 210000003934 vacuole Anatomy 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000014493 Crataegus Nutrition 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001002545 Engelhardia roxburghiana Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000013232 NAFLD rodent model Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 235000019581 fat taste sensations Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 235000021070 high sugar diet Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000021142 long-term diet Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The embodiment of the invention discloses a traditional Chinese medicine composition for resisting nonalcoholic fatty liver disease and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 55-65 parts of raw coix, 35-45 parts of raw lotus leaves, 25-35 parts of raw astragalus mongholicus, 15-25 parts of raw hawthorn, 18-22 parts of scorched hawthorn fruits, 18-22 parts of poria cocos, 28-32 parts of fried bighead atractylodes rhizome, 8-12 parts of semen cassiae, 8-12 parts of dried orange peel, 8-12 parts of rose, 8-12 parts of albizia flowers, 8-10 parts of rhizoma pinellinae praeparata and 8-10 parts of vinegar curcuma. The traditional Chinese medicine composition provided by the invention improves the state of 'blood stasis, toxin and phlegm' of an organism from the angles of eliminating turbid pathogen and strengthening spleen, supplements qi and eliminates phlegm, is suitable for treating internal retention of phlegm-dampness, can effectively improve the development process of non-alcoholic fatty liver disease, and can be used for treating and preventing the non-alcoholic fatty liver disease.
Description
Technical Field
The embodiment of the invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for resisting nonalcoholic fatty liver diseases and a preparation method thereof.
Background
With the rapid development of economy and the improvement of the living standard of people, the proportion of overweight and obesity of adults is rapidly increasing. The overweight rate of adults aged 18-69 years in our country rises from 19.6% to 28.0% and the obesity rate rises from 3.3% to 5.2% between 2004 and 2010. Overweight and obesity in adults 18-64 years of age respectively rise at a rate of 4.3%,9.0% per year, and obesity is a serious threat to people's health. Emotional disturbance, excessive thought, anger and other bad emotional states are important factors for promoting the formation of obesity. The traditional Chinese medicine considers that obesity belongs to the categories of phlegm syndrome, edema and the like, the internal cause is congenital endowment deficiency, the external cause is overfeeding with fat and sweet, spleen deficiency and dampness obstruction, yin and yang imbalance, and obesity is mainly caused by deficiency and excess. The phlegm turbidity is considered by the modern doctors as an important pathological factor of obesity, the phlegm dampness is a main constitution influencing factor of overweight and obesity, and the important links for preventing and treating obesity complications and ensuring curative effect are to intervene in abdominal obesity from constitution.
Non-alcoholic fatty liver disease (non-alcoholic fattyliverdisease, NAFLD) is a series of diseases characterized by liver steatosis, and is a common cause of chronic liver disease worldwide. Currently, the prevalence of NAFLD in the global world is about 25% of the world population, and it is expected that prevalence of NAFLD in 2030 can reach 33.5% and has become a significant challenge in severely threatening public health. NAFLD has been known to be closely related to metabolic disorders such as obesity, dyslipidemia, hypertension, and the like. Long-term diets that are too greasy, high-sugar diets, lack of exercise, obesity, genetic factors, and the like are considered susceptibility factors for NAFLD. In China, along with the improvement of living standard, the disease becomes frequently-occurring disease and common disease, and the disease incidence is gradually increasing year by year. In the more abundant areas of China, the community prevalence of NAFLD is about 15%. If not treated, 15% -25% of non-alcoholic steatohepatitis may progress to cirrhosis within 10 years.
Modern medicine has no medicine for effectively curing NAFLD, but on the basis of improving life style, symptomatic treatment, such as blood fat rise, is carried out according to the abnormality indexes detected by auxiliary examination and laboratory, and lipid-lowering medicine is used for treatment; elevation of transaminase, treatment with liver protecting and enzyme lowering drugs, and other symptomatic treatments. After stopping the medicine, the patient often shows symptoms again and the detection result is abnormal; however, for NAFLD patients with normal laboratory detection indexes and uncomfortable symptoms such as poor appetite, hypochondriac pain, hypodynamia and the like, the modern medicine is not in the way.
Disclosure of Invention
Therefore, the embodiment of the invention provides a traditional Chinese medicine composition for resisting nonalcoholic fatty liver disease and a preparation method thereof.
In order to achieve the above object, the embodiment of the present invention provides the following technical solutions:
according to a first aspect of the embodiment of the invention, the invention provides a traditional Chinese medicine composition for resisting nonalcoholic fatty liver disease, which comprises the following raw materials in parts by weight: 55-65 parts of raw coix, 35-45 parts of raw lotus leaves, 25-35 parts of raw astragalus mongholicus, 15-25 parts of raw hawthorn, 18-22 parts of scorched hawthorn fruits, 18-22 parts of poria cocos, 28-32 parts of fried bighead atractylodes rhizome, 8-12 parts of semen cassiae, 8-12 parts of dried orange peel, 8-12 parts of rose, 8-12 parts of albizia flowers, 8-10 parts of rhizoma pinellinae praeparata and 8-10 parts of vinegar curcuma.
Further, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 60 parts of raw coix, 40 parts of raw lotus leaf, 30 parts of raw astragalus, 20 parts of raw hawthorn, 20 parts of scorched hawthorn fruit, 20 parts of poria cocos, 30 parts of stir-fried bighead atractylodes rhizome, 10 parts of semen cassiae, 10 parts of dried orange peel, 10 parts of rose, 10 parts of albizia flower, 9 parts of rhizoma pinellinae praeparata and 9 parts of vinegar zedoary.
Further, the traditional Chinese medicine composition also comprises pharmaceutically acceptable auxiliary materials.
Further, the dosage forms of the traditional Chinese medicine composition comprise decoction, paste, powder, granules and pills.
According to a second aspect of the embodiment of the present invention, the present invention provides a method for preparing the traditional Chinese medicine composition for resisting non-alcoholic fatty liver disease, wherein the dosage form of the traditional Chinese medicine composition is decoction, and the preparation method comprises: weighing the raw materials according to the formula, soaking in water, heating to boil, and decocting.
Further, the water is used in an amount of 8 to 10 times the total weight of the raw materials.
Further, the soaking time is 20-30min.
Further, the decoction time is 40-80min.
NAFLD is a metabolic stress injury disease of liver except alcohol and other definite causes, and is mainly characterized by hepatic parenchymal cell steatosis and fat accumulation, and the disease is closely related to factors such as genetic susceptibility, insulin resistance and the like. There is no discussion about NAFLD in classical Chinese medicine books. The modern Chinese medicine believes that the disease is mainly caused by excessive lipid aggregation of liver cells, can be classified into the categories of turbid phlegm, blood stasis, accumulation and the like according to symptoms and main clinical characteristics of the disease, and the traditional Chinese medicine disease name of fatty liver disease is defined as liver nodule by the national Chinese medicine administration at present.
Wang Xinliang by utilizing the traditional Chinese medicine constitution survey scale formulated by Wang Qi, carrying out constitution type analysis on 300 NAFLD patients in a questionnaire investigation mode, finding that 4 constitution distributions in the patients are the most, namely phlegm-dampness mass (42.0%), qi deficiency mass (15.3%), damp-heat mass (14.0%), blood stasis mass (11.7%), and the like, wherein the factors such as age, constitution index, eating habit and the like have correlation with the constitution types, and the NAFLD patients which are particularly 30-50 years old are mainly phlegm-dampness mass; obese and overweight patients are mostly of phlegm-damp mass; the people who drink the food with preference for fat and sweet taste are mostly phlegm-damp mass, and the most common syndrome of phlegm-damp mass is the syndrome of internal retention of phlegm-damp.
The embodiment of the invention has the following advantages:
in the recipe, raw coix seed is used for promoting the circulation of dampness and strengthening the spleen, and clearing the dampness of intestines and stomach; the raw lotus leaves are more on the water surface, the veins on the leaves are wide, can move along the collaterals and are light and clear products, the two medicines are homologous in medicine and food, and the main medicines are all monarch medicines; huang Qi is used for tonifying qi and middle energizer and preventing excessive dryness due to its slight warm nature; the raw hawthorn and the burnt hawthorn can promote digestion, promote qi circulation, remove blood stasis, remove food stagnation and blood stasis of middle energizer, and the three medicines are ministerial medicines; chen Pi has the actions of invigorating spleen and regulating qi, and can be combined with ban Xia to dry middle energizer dampness and resolve phlegm for spleen accumulation; atractylodis rhizoma and Poria have effects of invigorating spleen and invigorating qi, and also have effects of eliminating turbid pathogen and promoting diuresis, and can regulate cold and warm properties of the drugs; curcumae rhizoma can enter liver and spleen meridians, enter blood, promote qi circulation, promote blood circulation, and remove food retention and distention; semen Cassiae is cold and cool in nature and can clear heat accumulated in stomach and intestine; flos Rosae Rugosae and flos Albiziae have effects of activating qi-flowing, relieving pain, activating spleen, and dispersing stagnated liver qi, and can be used as adjuvant drug. The recipe takes dampness resolving, spleen invigorating and qi tonifying as the core, and liver qi soothing is achieved when dampness is turbid and spleen qi is filled. The traditional Chinese medicine composition provided by the invention improves the state of 'blood stasis, toxin and phlegm' of an organism from the angles of eliminating turbid pathogen and strengthening spleen, and is suitable for treating the internal retention of phlegm-dampness, and the syndrome has great correlation with the pathological states of inflammation, insulin resistance and hyperlipidemia in modern medicine.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below. It will be apparent to those of ordinary skill in the art that the drawings in the following description are exemplary only and that other implementations can be obtained from the extensions of the drawings provided without inventive effort.
FIG. 1 shows the effect of the Chinese medicinal composition provided by the invention on liver lipid metabolism of NAFLD rats;
FIG. 2 shows the effect of the Chinese medicinal composition on NAFLD rat liver (x 100);
FIG. 3 shows the effect of the Chinese medicinal composition on NAFLD rat serum TNF-alpha and IL-13n＝10，pg/ml)；
FIG. 4 shows the effect of the Chinese medicinal composition on NAFLD rat liver ABCA1, LXRalpha and GAPDH proteinn＝10)；
FIG. 5 shows the effect of the Chinese medicinal composition on NAFLD rat liver LXRalpha and ABCA1 proteinn＝10)。
Detailed Description
Other advantages and advantages of the present invention will become apparent to those skilled in the art from the following detailed description, which, by way of illustration, is to be read in connection with certain specific embodiments, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The medicinal materials used in the embodiment of the invention are all commercial products. Unless specifically indicated, the technical means used in the embodiments of the present invention are conventional means well known to those skilled in the art.
Example 1
The embodiment provides a traditional Chinese medicine composition for resisting nonalcoholic fatty liver disease, which comprises the following raw materials in parts by weight: 60 parts of raw coix, 40 parts of raw lotus leaf, 30 parts of raw astragalus, 20 parts of raw hawthorn, 20 parts of scorched hawthorn fruit, 20 parts of poria cocos, 30 parts of stir-fried bighead atractylodes rhizome, 10 parts of semen cassiae, 10 parts of dried orange peel, 10 parts of rose, 10 parts of albizia flower, 9 parts of rhizoma pinellinae praeparata and 9 parts of vinegar zedoary.
Example 2
The embodiment provides a traditional Chinese medicine composition for resisting nonalcoholic fatty liver disease, which comprises the following raw materials in parts by weight: 65 parts of raw coix, 36 parts of raw lotus leaf, 35 parts of raw astragalus, 25 parts of raw hawthorn, 20 parts of scorched hawthorn fruit, 18 parts of poria cocos, 28 parts of stir-fried bighead atractylodes rhizome, 10 parts of semen cassiae, 12 parts of dried orange peel, 10 parts of rose, 10 parts of albizia flower, 10 parts of rhizoma pinellinae praeparata and 10 parts of vinegar zedoary.
Example 3
The embodiment provides a traditional Chinese medicine composition for resisting nonalcoholic fatty liver disease, which comprises the following raw materials in parts by weight: 55 parts of raw coix, 42 parts of raw lotus leaves, 28 parts of raw astragalus, 16 parts of raw hawthorns, 20 parts of scorched hawthorns, 22 parts of poria cocos, 28 parts of stir-fried bighead atractylodes rhizome, 10 parts of semen cassiae, 8 parts of dried orange peel, 10 parts of roses, 12 parts of albizia flowers, 9 parts of rhizoma pinellinae praeparata and 10 parts of vinegar curcuma zedoary.
Example 4
The embodiment provides a decoction for resisting nonalcoholic fatty liver disease, which is prepared by the following steps:
soaking the Chinese medicinal composition of example 1 in 8 times of water for 30min, heating to boil, decocting for 60min, filtering, concentrating, cooling, and fixing volume to obtain medicinal liquid containing 3g crude drug/mL.
Test examples
1. Experimental procedure
1.1 animals and feeding
To exclude the influence of sex difference on the experiment, 48 SPF-class SD male rats, 200+ -20 g, were selected this time. The animals are fed in the animal room with the temperature of about 20-25 ℃, the humidity of 40-60% and the indoor wind speed of about 0.1-0.2 m/s and natural lighting, and 5 animals are fed in each cage.
1.2 preparation of high-fat feed
The compound high-fat feed selected in the experiment is prepared from 81.3% of basic feed, 3% of cholesterol, 0.2% of propylthiouracil, 0.5% of sodium cholate, 5% of white sugar and 10% of lard.
1.3 group drug intervention
After purchasing from animals, the animals were fed free with water and adapted for one week. The method comprises the steps of weighing, randomly dividing into a blank control group, a model group, a traditional Chinese medicine high-dose group and a traditional Chinese medicine low-dose group, feeding 12 groups of traditional Chinese medicines except the blank group with high-fat feed, randomly taking 2 rat liver rows HE for 8 weeks, determining that the stomach is filled after molding, and continuously filling the stomach for 6 weeks to obtain the materials.
The random method comprises the following steps: the 48 rats are orderly numbered 1,2,3 and … … according to the weight from light to heavy, are completely randomly divided into 4 groups, and then the random grouping digital table is generated by SPSS19.0 statistical software.
1.4 design of dosing dosage
In this experiment, the decoction of example 4 was used as a therapeutic drug, and the drug was administered at a concentration of 3g/ml in accordance with a gastric lavage dose of 1ml/100 g. The experimental rats of each administration group are administrated with an equivalent dose (278 x 0.018 x 5, namely, 25.02 g/kg/d) of a conventional dose (278 g/d, namely, 4.63 g/kg/d) of an adult (weight is calculated according to 60 kg), the weight of the rats is calculated as 200g, the high dose is 2 times of the low dose, and the concentration is calculated according to the drug content, so that the daily administration doses of the high and low dose groups are respectively equivalent to 25.02g/kg (weight of the rats) and 50.04g/kg (weight of the rats) of crude drugs, the stomach irrigation volume is 1ml/100 g/time, the traditional Chinese medicine is administrated to the high and low dose groups for stomach irrigation, and the blank group and the model group are administrated with an equal volume of normal saline for 1 time every 12 hours.
1.5 sampling of laboratory animal specimens
Body weight was weighed weekly and blood was drawn from the tail tip at week 8. Material selection at week 14: injecting the sultai 5050ml/kg of anesthesia into the abdominal cavity, fixing the abdominal cavity on a rat plate in a supine mode, preparing the skin on the neck and the chest, stripping the complete liver of the rat by using a glass split needle, slightly flushing the liver by using normal saline, immediately fixing the liver in 10% neutral formalin solution and liquid nitrogen, and detecting pathology and Westernblot. Thereafter, the abdominal median skin and muscle of the rat were cut, and the abdominal aorta was separated, and about 6ml of blood was collected. Naturally coagulating the blood at room temperature for 20min, centrifuging at 4deg.C for 20min at 3000r/min, separating serum, and storing at-20deg.C in refrigerator.
1.6 detection of serum indicators
Serum sample treatment: the product is taken out of the refrigerator at-20℃and centrifuged again if precipitation occurs. The operation steps are as follows: the enzyme-linked immunosorbent assay is used for detecting the content of Triacylglycerol (TG), cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), TNF-alpha and IL-13 in serum. Serum samples were withdrawn 30 minutes in advance and manipulated according to the kit instructions. At the detection time point, four blood lipid items are detected at the 8 th week. Four items of blood lipid, TNF-alpha and IL-13 were tested at week 14.
1.7Westernblot detection for detecting expression of rat liver ABCA1 and LXR-alpha proteins
Weighing 20g of liver tissue, extracting protein from high-efficiency cell lysate, measuring protein concentration by using a BCA kit, adjusting the protein concentration of each group, boiling for 5min in a boiling water bath to denature the protein, performing SDS-PAGE electrophoresis, transferring to a PVDF membrane, sealing, sequentially incubating a primary antibody and a secondary antibody, washing the membrane, adding a developer, developing and exposing by using a Chemi Doc XRS chemiluminescence imaging system, and analyzing the band gray value by using Image Lab software.
1.8 statistical methods charts were drawn and statistical analysis using GraphPadPrism 8.0.2 software toA formal representation; two sets of mean comparisons were tested using Student's t, and multiple sets of mean comparisons were analyzed using One-wayANOVA, when P<A difference of 0.05 is statistically significant.
2 results
2.1 Effect of the Chinese medicinal composition provided by the invention on liver lipid metabolism of NAFLD rats
The liver is mainly observed to be reddish brown in blank group rat liver, the surface is smooth, the edge is sharp, and the morphology is normal; the liver of the model group rat is grey yellow, the surface touch is accompanied by greasy feel, the edge is blunt and enlarged, the model group rat has the formation of a plaque block, and a small amount of white fat deposition is partially visible; the liver color of the rats in each traditional Chinese medicine group is gradually recovered to be normal, the liver fat transformation degree is obviously improved, and the liver fat transformation degree is related to the administration dosage. (see FIG. 1)
Liver HE staining shows that the liver cells of the mice in the blank group are arranged normally; the liver cells of the model group are arranged in disorder, liver sinuses become fewer, and a large number of fat vacuoles appear; compared with the model group, the liver injury degree of the traditional Chinese medicine low and high dose groups is obviously reduced compared with the model group, the fat vacuoles are reduced, and the liver sinus injury is recovered. (see FIG. 2)
2.2 effects of the Chinese medicinal composition provided by the invention on NAFLD rat serum TNF-alpha and IL-13
The model group had elevated TNF- α expression (P < 0.01) and decreased IL-13 expression (P < 0.01) compared to the normal control group. Serum containing drug at each concentration reduced serum TNF- α content (P < 0.05) and increased IL-13 content (P < 0.01) compared to the model group. (see FIG. 3, wherein P < 0.05P < 0.01)
2.3 Effect of the Chinese medicinal composition provided by the invention on NAFLD rat liver ABCA1, LXR-alpha protein expression
Model groups ABCA1, LXR- α were decreased (P < 0.01) compared to normal control group. Compared with the model group, the traditional Chinese medicine group in each dose group promotes LXR-alpha and ABCA1 expression (P < 0.01). (see figures 4, 5, wherein P < 0.05P < 0.01)
2.4 influence of the Chinese medicinal composition provided by the invention on NAFLD rat blood lipid
The high dose group of traditional Chinese medicine can significantly reduce serum LDL of rats (P < 0.05). (see Table 1)
TABLE 1
*P<0.05
3. Discussion of the invention
ABCA1 has been found to play an important role in cholesterol transport by using ATP as an energy transport molecule such as cholesterol and phospholipid. Abnormal cholesterol metabolism is involved in the pathogenesis of NAFLD and liver fibrosis. Studies report that liver ABCA1 protein levels were significantly reduced in patients. ABCA1 is regulated by Liver X Receptors (LXRs), and activation of LXR- α increases ABCA1 expression and increases the ability of cells to transport cholesterol. Activating LXR-ABCA1 pathway is a hotspot in lipid-lowering drug research.
The research shows that the expression level of LXR-alpha and ABCA1 proteins in the liver of a NAFLD model rat is obviously reduced, the expression of LXR-alpha is down-regulated so as to influence the expression of ABCA1, the expression of the liver ABCA1 is reduced, the outflow level of cholesterol is influenced, the cholesterol is accumulated in the liver, and lipid deposition, inflammation, fibrosis and the like are further induced, so that NAFLD is generated.
Studies show that TNF-alpha can obviously inhibit the activity of an LXR-alpha promoter, influence the effect of regulating cholesterol outflow and interfere the lipid metabolism process. IL-13 has the ability to induce macrophage transformation into alternative activated macrophages, thereby down-regulating the immune response and thus inhibiting inflammatory responses. The experimental study results show that compared with the traditional Chinese medicine composition of the invention, the model group can reduce the TNF-alpha content (P < 0.05) in NAFLD rat serum and increase the IL-13 content.
Meanwhile, experimental researches show that after the traditional Chinese medicine composition is administered for treatment, the expression level of the liver LXR-alpha and ABCA1 proteins of NAFLD rats is in a trend of increasing, and the NAFLD rats are considered to activate the LXR-ABCA1 pathway, promote the outflow of liver cholesterol, further reduce inflammation caused by accumulation and delay the development process of NAFLD.
In combination with the blood lipid level and HE staining results, it is found that NAFLD rat blood lipid disorder is improved, liver cell swelling is reduced, and fat vacuoles and lipid deposition are reduced after the treatment by the traditional Chinese medicine composition.
The above results prove the therapeutic effect of the traditional Chinese medicine composition provided by the invention on NAFLD.
While the invention has been described in detail in the foregoing general description and specific examples, it will be apparent to those skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.
Claims (8)
1. The traditional Chinese medicine composition for resisting the nonalcoholic fatty liver disease is characterized by comprising the following raw materials in parts by weight: 55-65 parts of raw coix, 35-45 parts of raw lotus leaves, 25-35 parts of raw astragalus mongholicus, 15-25 parts of raw hawthorn, 18-22 parts of scorched hawthorn fruits, 18-22 parts of poria cocos, 28-32 parts of fried bighead atractylodes rhizome, 8-12 parts of semen cassiae, 8-12 parts of dried orange peel, 8-12 parts of rose, 8-12 parts of albizia flowers, 8-10 parts of rhizoma pinellinae praeparata and 8-10 parts of vinegar curcuma.
2. The traditional Chinese medicine composition for resisting nonalcoholic fatty liver disease according to claim 1, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 60 parts of raw coix, 40 parts of raw lotus leaf, 30 parts of raw astragalus, 20 parts of raw hawthorn, 20 parts of scorched hawthorn fruit, 20 parts of poria cocos, 30 parts of stir-fried bighead atractylodes rhizome, 10 parts of semen cassiae, 10 parts of dried orange peel, 10 parts of rose, 10 parts of albizia flower, 9 parts of rhizoma pinellinae praeparata and 9 parts of vinegar zedoary.
3. The traditional Chinese medicine composition for resisting non-alcoholic fatty liver disease according to claim 1 or 2, wherein the traditional Chinese medicine composition further comprises pharmaceutically acceptable auxiliary materials.
4. The traditional Chinese medicine composition for resisting nonalcoholic fatty liver disease according to claim 3, wherein the dosage form of the traditional Chinese medicine composition comprises decoction, paste, powder, granules and pills.
5. The method for preparing the traditional Chinese medicine composition for resisting non-alcoholic fatty liver disease according to any one of claims 1 to 4, wherein the preparation of the traditional Chinese medicine composition is decoction, and the preparation method comprises the following steps:
weighing the raw materials according to the formula, soaking in water, heating to boil, and decocting.
6. The method for preparing a Chinese medicinal composition for treating non-alcoholic fatty liver disease according to claim 5, wherein the amount of water is 8-10 times of the total weight of the raw materials.
7. The method for preparing a Chinese medicinal composition for treating non-alcoholic fatty liver disease according to claim 5, wherein the soaking time is 20-30min.
8. The method for preparing a Chinese medicinal composition for treating non-alcoholic fatty liver disease according to claim 5, wherein the time of the decoction is 40-80min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311159817.9A CN117018143A (en) | 2023-09-08 | 2023-09-08 | Traditional Chinese medicine composition for resisting non-alcoholic fatty liver disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311159817.9A CN117018143A (en) | 2023-09-08 | 2023-09-08 | Traditional Chinese medicine composition for resisting non-alcoholic fatty liver disease and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117018143A true CN117018143A (en) | 2023-11-10 |
Family
ID=88639290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311159817.9A Pending CN117018143A (en) | 2023-09-08 | 2023-09-08 | Traditional Chinese medicine composition for resisting non-alcoholic fatty liver disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117018143A (en) |
-
2023
- 2023-09-08 CN CN202311159817.9A patent/CN117018143A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110075216A (en) | It is a kind of with the food compositions and preparation method thereof, preparation and the application that assist reducing blood lipid, hepatoprotective effect of losing weight | |
| CN102048902B (en) | Hepatitis treating traditional Chinese medicine composition, extract and preparation method, application and formulation | |
| CN107137420A (en) | A kind of mulberry leaf-chrysanthemum Chinese yam complex polysaccharide with clearing heat and nourishing yin function of blood sugar reduction and preparation method thereof | |
| CN106562165A (en) | Slimming type blended fruit-vegetable juice drink and preparation method thereof | |
| CN105687480A (en) | Immunoregulatory traditional Chinese medicine composition and preparation | |
| CN115252737A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease, preparation method and application | |
| CN105079532A (en) | Healthcare green tea capable of reducing blood fat and loosing weight and preparation method of healthcare green tea | |
| CN117018143A (en) | Traditional Chinese medicine composition for resisting non-alcoholic fatty liver disease and preparation method thereof | |
| CN101757499B (en) | Traditional Chinese medicine composite for treating impaired glucose tolerance | |
| CN103920140A (en) | Compound preparation for reducing blood glucose, body weight and fat for human | |
| CN105147915B (en) | Yiganbao soft capsule and its preparation process | |
| CN108452240A (en) | A kind of antitumor Chinese medicine composition and its application | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| CN109394885A (en) | A kind of Chinese materia medica preparation of anti-nonalcoholic fatty liver | |
| CN118403116B (en) | A pharmaceutical composition for relieving obesity and its preparation method | |
| CN108514093A (en) | A kind of multifunctional food composition of auxiliary hyperglycemic and preparation method thereof | |
| CN117180340B (en) | Composition for reducing blood fat and preparation method and application thereof | |
| CN111228422B (en) | Traditional Chinese medicine composition for reducing intramuscular fat of chicken and preparation method thereof | |
| CN112022982A (en) | Traditional Chinese medicine composition for treating qi deficiency and preparation method and application thereof | |
| CN118403103A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver and preparation method thereof | |
| CN117695359A (en) | Compound fermentation liquor of four-mulch pill as well as preparation method and application thereof | |
| CN118615415A (en) | Traditional Chinese medicine composition for treating helicobacter pylori as well as preparation and application thereof | |
| CN118634296A (en) | A medicinal and edible composition for reducing carbohydrate sugar increasing effect | |
| CN118593667A (en) | Lily-containing traditional Chinese medicine compound preparation for treating depression | |
| CN115969950A (en) | Traditional Chinese medicine composition for preventing and treating diabetic peripheral neuropathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |